Fundraising Fox
/Companies
Sign in

Retrotope

Los Altos Hills, US · Delaware corporation

Find your way into Retrotope

259 people in our graph share verified history with the Retrotope team — schools, employers, funds. One of them is your warm intro.

Casper de Clercqunlockedknows Vidhya Gopalakrishnan · together at Aerogen (overlapped)
×3knows the team · via Osmania University
knows the team · via Stanford University School of Medicine
×7knows the team · via ALZA Corporation, J&J

Retrotope is a clinical-stage biopharmaceutical company developing proprietary therapeutics that down-regulate lipid peroxidation to treat degenerative diseases, including neurodegenerative conditions such as INAD, Friedreich's ataxia, ALS, and PSP, as well as dry age-related macular degeneration. Its drug candidates are based on stabilized polyunsaturated fatty acids from its proprietary drug discovery platform.

BiotechDigital Health

Founders & leadership

MSMikhail Shchepinov
Mikhail ShchepinovFounder and CSO; Director
RM
Robert MolinariCo-founder
CCCharles Cantor
Charles CantorExecutive
AKAnil Kumar
Anil KumarPresident
PGPeter G. Milner
Peter G. MilnerCMO
VGVidhya Gopalakrishnan
Vidhya GopalakrishnanCDOVidhya Gopalakrishnan is Chief Development Officer at Retrotope and brings over 25 years of research and development and program leadership experience in biotech and pharmaceuticals, with expertise spanning drug development programs from preclinical through Phase 3 clinical trials across therapeutic areas including diabetes, infectious disease, neurodegenerative conditions, and bone health.

Board

RF
Robert F. JohnstonBoard director
HS
Harry SaalBoard director
LH
Leonardus H.T. Van der PloegBoard director

Funding

SEC filings, press & company announcements

$83.5M disclosed across 8 of 9 rounds · 2014–2021

▶$25.5MraisedMay 2021 · 39 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • George GaribaldiDirector
  • Nitin MehtaDirector
  • Mikhail ShchepinovExecutive Officer, Director
  • Corey McCannDirector
  • Yvonne KaoExecutive Officer
  • Anil KumarExecutive Officer, Director
Offering amount
$58.3M
Amount sold
$25.5M
First sale
Aug 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.1MraisedJul 2019 · 28 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Leonardus H.T. Van der PloegDirector
  • Nitin MehtaDirector
  • Charles CantorExecutive Officer, Director
  • Robert MolinariExecutive Officer, Director
  • Ernst-Guenter AftingDirector
  • Peter MilnerDirector
  • Timur ArtemevDirector
  • Harry SaalDirector
  • Mikhail ShchepinovExecutive Officer, Director
Offering amount
$4.1M
Amount sold
$4.1M
First sale
Jul 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$20MraisedJul 2019 · 37 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Peter MilnerDirector
  • Timur ArtemevDirector
  • Harry SaalDirector
  • Leonardus H.T. Van der PloegDirector
  • Mikhail ShchepinovExecutive Officer, Director
  • Charles CantorExecutive Officer, Director
  • Robert MolinariExecutive Officer, Director
  • Ernst-Guenter AftingDirector
Offering amount
$20.9M
Amount sold
$20M
Minimum investment
$1
First sale
Nov 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.3MraisedDec 2018 · 40 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert MolinariExecutive Officer, Director
  • Charles CantorExecutive Officer, Director
  • Leonardus H.T. Van der PloegDirector
  • Harry SaalDirector
  • Peter MilnerDirector
  • Ernst-Guenter AftingDirector
  • Timur ArtemevDirector
  • Mikhail ShchepinovExecutive Officer, Director
Offering amount
$4.3M
Amount sold
$4.3M
Minimum investment
$1
First sale
Nov 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.4MraisedJan 2018 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Harry SaalDirector
  • Charles CantorExecutive Officer, Director
  • Ernst-Guenter AftingDirector
  • Peter MilnerDirector
  • Leonardus H.T. Van der PloegDirector
  • Mikhail ShchepinovExecutive Officer, Director
  • Robert MolinariExecutive Officer, Director
  • Timur ArtemevDirector
Offering amount
$3M
Amount sold
$2.4M
Minimum investment
$1
First sale
Dec 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.7MraisedNov 2016 · 26 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Leonardus H.T. Van der PloegDirector
  • Charles CantorExecutive Officer, Director
  • Mikhail ShchepinovExecutive Officer, Director
  • Ernst-Guenter AftingDirector
  • Robert MolinariExecutive Officer, Director
  • Harry SaalDirector
  • Peter MilnerDirector
  • Timur ArtemevDirector
Offering amount
$10M
Amount sold
$2.7M
Minimum investment
$1
First sale
Nov 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10MraisedJan 2015 · 46 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert F. JohnstonDirector
  • Mikhail ShchepinovDirector
  • Harry SaalDirector
  • Charles CantorExecutive Officer, Director
  • Robert MolinariExecutive Officer, Director
  • Leonardus H.T. Van der PloegDirector
Offering amount
$10M
Amount sold
$10M
Minimum investment
$1
First sale
May 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap
Eli Lilly7 shared keywordsEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Applied Therapeutics6 shared keywordsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
Hatchcollection6 shared keywordsHATCH is a direct-to-consumer apparel brand offering maternity and pregnancy clothing, including tees, pants, jeans, and cardigans, along with body care products like belly oil. It targets expectant mothers seeking stylish, wearable maternity wear.

Companies competing with Retrotope for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Retrotope do?
Retrotope is a clinical-stage biopharmaceutical company developing proprietary therapeutics that down-regulate lipid peroxidation to treat degenerative diseases, including neurodegenerative conditions such as INAD, Friedreich's ataxia, ALS, and PSP, as well as dry age-related macular degeneration. Its drug candidates are based on stabilized polyunsaturated fatty acids from its proprietary drug discovery platform.
Who founded Retrotope?
Retrotope was founded by Mikhail Shchepinov, Robert Molinari.
How much funding has Retrotope raised?
Retrotope has disclosed $83.5M raised across 8 of its 9 known rounds.
Where is Retrotope headquartered?
Retrotope is headquartered in Los Altos Hills, US.